home / stock / nby / nby news


NBY News and Press, NovaBay Pharmaceuticals Inc. From 11/02/23

Stock Information

Company Name: NovaBay Pharmaceuticals Inc.
Stock Symbol: NBY
Market: NYSE
Website: novabay.com

Menu

NBY NBY Quote NBY Short NBY News NBY Articles NBY Message Board
Get NBY Alerts

News, Short Squeeze, Breakout and More Instantly...

NBY - NovaBay Pharmaceuticals to Hold Third Quarter 2023 Conference Call on November 9, 2023

NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and nine months ended September 30, 2023 after market close on Thursday, November 9, 2023 and will hold an investment community conference call that day beginning at 4:30 ...

NBY - NovaBay Pharmaceuticals Expands Physician Dispensed Sales Channel with New Avenova Programs

NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces the launch of two new promotional programs for ophthalmologists and optometrists who help their patients manage the symptoms of...

NBY - NovaBay Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that Justin Hall, CEO and General Counsel, will present a company overview and hold investor meetings at the 8 th Annual Dawson Ja...

NBY - Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference

JUPITER, Fla., Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Dawson James Securities, Inc. (“Dawson”), a full-service investment bank focused on emerging growth companies, today announces its 8 th Annual Dawson James Small Cap Growth Conferen...

NBY - NovaBay Pharmaceuticals Announces Commercial Launch of Avenova® Allograft

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces the commercial launch of Avenova Allograft to eyecare professionals across the U.S. through its physician-dispensed channel. This prescription product is the only optic allograft manufactured using BioStem Technologies, Inc.’...

NBY - NovaBay stock soars 86% on optic allograft product deal

2023-09-11 09:49:45 ET More on NovaBay Seeking Alpha’s Quant Rating on NovaBay Historical earnings data for NovaBay Financial information for NovaBay NovaBay Pharmaceuticals, Inc. ( NBY ) Q2 2023 Earnings Call Transcript For further details...

NBY - NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova® Allograft

NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and BioStem Technologies, Inc. (OTC: BSEM) announce an agreement under which NovaBay has been granted the right to commercialize BioStem Technologies’ Amniotic Tissue Allograft, which is intended for use as a protective covering during the...

NBY - NioBay commences its 2023 drilling campaign at the Crevier project

MONTRÉAL, Aug. 29, 2023 (GLOBE NEWSWIRE) -- NioBay Metals inc. (“NioBay” or the “Company”) (TSX-V: NBY) (OTCQB: NBYCF) is pleased to announce the start of a drilling campaign on the Crevier Property, which is owned by Les Minéraux Crevier Inc, of which NioBay...

NBY - NovaBay GAAP EPS of -$1.27 misses by $0.71, revenue of $4.61M beats by $0.94M

2023-08-10 16:10:51 ET NovaBay press release ( NYSE: NBY ): Q2 GAAP EPS of -$1.27 misses by $0.71 . Revenue of $4.61M (+28.1% Y/Y) beats by $0.94M . For further details see: NovaBay GAAP EPS of -$1.27 misses by $0.71, revenue of $4.61M beats by $0.94M

NBY - NovaBay Pharmaceuticals Reports Second Quarter 2023 Financial Results

Net product revenue of $4.6 million increased 26% over the prior-year quarter Wound care sales of $1.3 million mark a record quarterly high Sales and marketing expenses reduced by 16% through optimized digital marketing programs Operating loss decreased by 37% year-over-ye...

Previous 10 Next 10